Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Lymphoma: predicting response

Frederick Locke • 2 Jun 2019
ASCO 2019
Lymphoma Axicabtagene ciloleucel

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the methods that can be used to predict durable response in lymphoma patients being treated with CAR T-cell therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

15:38
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
Frederick Locke et al. • 1 May 2022
3:52
Impact of age and co-morbidities on axi-cel efficacy
Frederick Locke • 29 Nov 2021
6:37
ZUMA-7: Axi-cel in r/r large B-cell lymphoma
Frederick Locke • 29 Nov 2021
1:15
The benefits of second-line CAR-T cell therapy
Frederick Locke • 29 Nov 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals